Sevelamer
From Wikipedia, the free encyclopedia
 |
|
|
Sevelamer
|
|
| Systematic (IUPAC) name | |
| poly(allylamine- co-N,N'-diallyl-1,3-diamino-2-hydroxypropane) |
|
| Identifiers | |
| CAS number | |
| ATC code | V03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | [(C3H7N)a+b.(C9H17N2O)c]m where a+b:c = 9:1 |
| Mol. mass | variable |
| Pharmacokinetic data | |
| Bioavailability | nil |
| Metabolism | nil |
| Half life | n/a |
| Excretion | faecal 100% |
| Therapeutic considerations | |
| Pregnancy cat. |
B3 (Australia) |
| Legal status |
Schedule 4 (Australia) |
| Routes | oral |
Sevelamer (rINN) (IPA: [sɛˈvɛləmə, -mər, -mir]) is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel.
Contents |
[edit] Chemistry and pharmacology
Sevelamer is a copolymer of 2-(chloromethyl)oxirane (epichlorohydrin) and prop-2-en-1-amine. The marketed form sevelamer hydrochloride is a partial hydrochloride salt being present as approximately 40% amine hydrochloride and 60% sevelamer base. The amine groups of sevelamer become partially protonated in the intestine and interact with phosphorus molecules through ionic and hydrogen bonding.
[edit] Clinical use
[edit] Indications
Sevelamer is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic renal failure (end stage renal disease).
[edit] Contraindications
Sevelamer therapy is contraindicated in hypophosphataemia or bowel obstruction.
[edit] Adverse effects
Common adverse drug reactions (ADRs) associated with the use of sevelamer include: hypotension, hypertension, nausea and vomiting, dyspepsia, diarrhea, flatulence, and/or constipation.
